Results 51 to 60 of about 14,520 (202)

Fulvestrant revisited:Efficacy and safety of the 500-mg dose

, 2011
Postmenopausal women with hormone receptor-positive advanced breast cancer are candidates for endocrine therapy. As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the ...
Howell, Anthony; id_orcid, Anthony Howell, Francisco Sapunar, Sapunar, Francisco   +3 more
core   +1 more source

The Effectiveness of Fulvestrant in postmenopausal advanced breast cancer; systematic review of clinical evidence

Journal of Pharmacoeconomics and Pharmaceutical Management, 2015
Background: In this study we aim to assess the clinical evidence on the effectiveness of Fulvestrant compared with other alternatives to explore whether it has any advantage in the treatment outcomes of postmenopausal advanced breast cancer or not ...
Amir Hashemi-Meshkini, Khosro Keshavarz, Mehdi Varmaghani, Abbas Kebriaeezadeh, Shekoufeh Nikfar   +4 more
doaj  

Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2− advanced or metastatic breast cancer

Frontiers in Pharmacology
ObjectiveThe aim of this study was to compare the cost-effectiveness of various CDK4/6 inhibitors plus fulvestrant with fulvestrant monotherapy in the second-line treatment for patients with HR+/HER2− advanced or metastatic breast cancer from the Chinese
Kaixuan Wang, Shixian Liu, Shunping Li, Jie Gao   +3 more
doaj   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2183-2192, July 2026.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. [PDF]

PLoS ONE, 2018
Insulin-like growth factor 1 receptor (IGF-1R) is an important therapeutic target for breast cancer treatment. The alteration in the IGF-1R associated signaling network due to various genetic and environmental factors leads the system towards metastasis.
Samra Khalid, Rumeza Hanif, Ishrat Jabeen, Qaisar Mansoor, Muhammad Ismail   +4 more
doaj   +1 more source

Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies

Pharmaceuticals, 2021
Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics.
Jiawang Liu, Nirmal Rajasekaran, Ahamed Hossain, Changde Zhang, Shanchun Guo, Borui Kang, Hunsoon Jung, Hongjoong Kim, Guangdi Wang   +8 more
doaj   +1 more source

Cervical Metastasis From Primary Breast Carcinoma: A Case Report and Review of Extragenital Tumors Involving the Uterine Cervix

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Cervical metastases from breast carcinoma should be considered in the differential diagnosis of uterine lesions in patients with prior breast cancer. Re‐biopsy is essential to detect receptor discordance (ER/PR up to 29%) and guide therapy. GCDFP‐15, mammaglobin, and GATA3 confirm mammary origin.
Mario Assenza, Adele Zappalà, Armando Nallbani, Jacopo Wabersich   +3 more
wiley   +1 more source

Functional grouping of fulvestrant resistance genes.

, 2014
Functional grouping of fulvestrant resistance genes.
Anker Hansen (214769), Elizabeth Anderson (20931), Justin Lindemann (520673), Wiktor Mazin (118965), Irene Kuter (520674), Thomas Jensen (92927), Naomi Laing (520675), Steen Knudsen (858)   +7 more
core   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Functional grouping of fulvestrant sensitivity genes.

, 2014
Functional grouping of fulvestrant sensitivity genes.
Anker Hansen (214769), Elizabeth Anderson (20931), Justin Lindemann (520673), Wiktor Mazin (118965), Irene Kuter (520674), Thomas Jensen (92927), Naomi Laing (520675), Steen Knudsen (858)   +7 more
core   +1 more source